AR103714A1 - Proteínas específicas para pioverdina y pioquelina - Google Patents
Proteínas específicas para pioverdina y pioquelinaInfo
- Publication number
- AR103714A1 AR103714A1 ARP160100413A ARP160100413A AR103714A1 AR 103714 A1 AR103714 A1 AR 103714A1 AR P160100413 A ARP160100413 A AR P160100413A AR P160100413 A ARP160100413 A AR P160100413A AR 103714 A1 AR103714 A1 AR 103714A1
- Authority
- AR
- Argentina
- Prior art keywords
- muteins
- pyoquelin
- polypeptide
- hngal
- present description
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108010025281 pyoverdin Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente descripción proporciona muteínas de hNGAL que se unen con un miembro de la familia de pioverdina o pioquelina y que pueden usarse en diversas aplicaciones incluyendo aplicaciones farmacéuticas, por ejemplo, para inhibir o reducir el crecimiento de P. aeruginosa. La presente descripción también se refiere a métodos para preparar una o más muteínas de unión a pioverdina o a pioquelina descritas en la presente memoria así como a composiciones que comprenden una o más de dichas muteínas. La presente descripción se refiere además a moléculas de ácido nucleico que codifican dichas muteínas y a métodos para la generación de dichas muteínas y moléculas de ácido nucleico. Además, la solicitud describe usos terapéuticos y/o de diagnóstico de estas muteínas así como composiciones que comprenden una o más de dichas muteínas. Reivindicación 1: Un polipéptido que tiene especificidad de unión por pioverdina de tipo I, II, III o pioquelina, en el que el polipéptido comprende una muteína de hNGAL que se une con pioverdina de tipo I, II, III o pioquelina con afinidad detectable. Reivindicación 2: El polipéptido de la reivindicación 1, en el que la muteína de hNGAL comprende un resto de aminoácido mutado en una o más posiciones correspondientes a las posiciones 28, 34, 36, 39 - 42, 44 - 47, 49, 52, 54 - 55, 65, 68, 70, 72 - 75, 77, 79 - 81, 87, 96, 100, 103, 106, 108, 123, 125, 127, 132, 134, 141 y 145 de la secuencia polipeptídica lineal de la hNGAL madura (SEC ID Nº 1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305242 | 2015-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103714A1 true AR103714A1 (es) | 2017-05-31 |
Family
ID=52595246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100413A AR103714A1 (es) | 2015-02-18 | 2016-02-16 | Proteínas específicas para pioverdina y pioquelina |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US9884898B2 (es) |
| EP (1) | EP3259282A1 (es) |
| JP (1) | JP6843754B2 (es) |
| KR (1) | KR20170116158A (es) |
| CN (1) | CN107660211A (es) |
| AR (1) | AR103714A1 (es) |
| AU (1) | AU2016221816B2 (es) |
| BR (1) | BR112017017530A2 (es) |
| CA (1) | CA2976687A1 (es) |
| CL (1) | CL2017002082A1 (es) |
| CO (1) | CO2017009433A2 (es) |
| CR (1) | CR20170425A (es) |
| DO (1) | DOP2017000191A (es) |
| EA (1) | EA035824B1 (es) |
| EC (1) | ECSP17061751A (es) |
| GT (1) | GT201700184A (es) |
| HK (1) | HK1245293A1 (es) |
| IL (1) | IL254013A0 (es) |
| MA (1) | MA41072A1 (es) |
| MX (1) | MX375049B (es) |
| PE (1) | PE20171652A1 (es) |
| PH (1) | PH12017501473A1 (es) |
| SG (1) | SG11201706621SA (es) |
| TN (1) | TN2017000348A1 (es) |
| TW (1) | TW201636364A (es) |
| UY (1) | UY36561A (es) |
| WO (1) | WO2016131804A1 (es) |
| ZA (1) | ZA201705257B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201408073XA (en) | 2009-12-07 | 2015-01-29 | Pieris Ag | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
| EP3145945B1 (en) | 2014-05-22 | 2020-07-15 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| BR112017015773A2 (pt) | 2015-01-28 | 2018-03-27 | Pieris Pharmaceuticals Gmbh | muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo |
| PE20171652A1 (es) * | 2015-02-18 | 2017-11-13 | Sanofi Sa | Nuevas proteinas especificas para pioverdina y pioquelina |
| SG11201708339QA (en) | 2015-05-04 | 2017-11-29 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| MX2017014083A (es) | 2015-05-04 | 2018-11-09 | Pieris Pharmaceuticals Gmbh | Polipeptido de fusion anti-cancer. |
| KR20180008649A (ko) | 2015-05-18 | 2018-01-24 | 피어이스 파마슈티컬즈 게엠베하 | 글리피칸-3(gpc3)에 대해 친화도를 갖는 인간 리포칼린 2의 뮤테인 |
| WO2016184882A1 (en) | 2015-05-18 | 2016-11-24 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| CN108699162A (zh) | 2015-11-30 | 2018-10-23 | 皮里斯澳大利亚有限公司 | 新型抗血管生成融合多肽 |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| WO2018087108A1 (en) * | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| EP3823667A4 (en) * | 2018-07-19 | 2022-07-27 | The Regents Of The University Of Colorado | Methods, systems and compositions for the novel use of enterobactin to treat iron deficiency and related anemia |
| US20220168387A1 (en) | 2019-03-29 | 2022-06-02 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| CN116077621A (zh) * | 2021-11-05 | 2023-05-09 | 华南农业大学 | P19蛋白在调控绿脓杆菌毒力中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| ID29285A (id) | 1998-06-08 | 2001-08-16 | Hoffmann La Roche | PENGGUNAAN PEG-IFN-α DAN RIBAVIRIN UNTUK PENGOBATAN HEPATITIS C KRONIS |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| JP4469456B2 (ja) * | 2000-04-19 | 2010-05-26 | 第一三共株式会社 | 緑膿菌鉄獲得系阻害物質のスクリーニング法 |
| WO2002076489A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| US7056702B2 (en) * | 2002-12-16 | 2006-06-06 | Kimberly Clark Co | Detecting lipocalin |
| WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| JP5711118B2 (ja) | 2008-06-24 | 2015-04-30 | テクニッシュ ウニヴェルジテート ミュンヘン | 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン |
| ES2667066T3 (es) * | 2010-05-24 | 2018-05-09 | The Trustees Of Columbia University In The City Of New York | Proteínas NGAL mutantes y usos de las mismas |
| EP2920202B1 (en) | 2012-11-19 | 2018-08-29 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| CN103074303A (zh) * | 2012-12-27 | 2013-05-01 | 中国人民解放军第三军医大学 | 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用 |
| PE20171652A1 (es) * | 2015-02-18 | 2017-11-13 | Sanofi Sa | Nuevas proteinas especificas para pioverdina y pioquelina |
| EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
-
2016
- 2016-02-16 PE PE2017001421A patent/PE20171652A1/es unknown
- 2016-02-16 EA EA201791841A patent/EA035824B1/ru not_active IP Right Cessation
- 2016-02-16 EP EP16704641.6A patent/EP3259282A1/en not_active Withdrawn
- 2016-02-16 MA MA41072A patent/MA41072A1/fr unknown
- 2016-02-16 BR BR112017017530-4A patent/BR112017017530A2/pt not_active IP Right Cessation
- 2016-02-16 SG SG11201706621SA patent/SG11201706621SA/en unknown
- 2016-02-16 TN TNP/2017/000348A patent/TN2017000348A1/en unknown
- 2016-02-16 CA CA2976687A patent/CA2976687A1/en not_active Abandoned
- 2016-02-16 AR ARP160100413A patent/AR103714A1/es unknown
- 2016-02-16 WO PCT/EP2016/053226 patent/WO2016131804A1/en not_active Ceased
- 2016-02-16 TW TW105104396A patent/TW201636364A/zh unknown
- 2016-02-16 KR KR1020177026032A patent/KR20170116158A/ko not_active Withdrawn
- 2016-02-16 CR CR20170425A patent/CR20170425A/es unknown
- 2016-02-16 JP JP2017543835A patent/JP6843754B2/ja not_active Expired - Fee Related
- 2016-02-16 MX MX2017010628A patent/MX375049B/es active IP Right Grant
- 2016-02-16 AU AU2016221816A patent/AU2016221816B2/en not_active Ceased
- 2016-02-16 CN CN201680022032.9A patent/CN107660211A/zh active Pending
- 2016-02-16 HK HK18104645.1A patent/HK1245293A1/zh unknown
- 2016-02-18 UY UY0001036561A patent/UY36561A/es not_active Application Discontinuation
-
2017
- 2017-05-23 US US15/602,783 patent/US9884898B2/en not_active Expired - Fee Related
- 2017-08-03 ZA ZA2017/05257A patent/ZA201705257B/en unknown
- 2017-08-14 PH PH12017501473A patent/PH12017501473A1/en unknown
- 2017-08-14 DO DO2017000191A patent/DOP2017000191A/es unknown
- 2017-08-14 CL CL2017002082A patent/CL2017002082A1/es unknown
- 2017-08-16 IL IL254013A patent/IL254013A0/en unknown
- 2017-08-17 GT GT201700184A patent/GT201700184A/es unknown
- 2017-09-15 EC ECIEPI201761751A patent/ECSP17061751A/es unknown
- 2017-09-18 CO CONC2017/0009433A patent/CO2017009433A2/es unknown
- 2017-10-05 US US15/726,163 patent/US10072056B2/en not_active Expired - Fee Related
- 2017-10-06 US US15/726,577 patent/US10065998B2/en not_active Expired - Fee Related
- 2017-10-06 US US15/727,087 patent/US10118952B2/en not_active Expired - Fee Related
- 2017-11-16 US US15/814,737 patent/US10329334B2/en not_active Expired - Fee Related
-
2018
- 2018-08-14 US US16/103,645 patent/US20180371037A1/en not_active Abandoned
- 2018-08-14 US US16/103,649 patent/US20180346532A1/en not_active Abandoned
- 2018-08-14 US US16/103,652 patent/US20180371038A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103714A1 (es) | Proteínas específicas para pioverdina y pioquelina | |
| BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
| BR112019005587A2 (pt) | proteínas de ligação recombinantes e sua utilização | |
| CL2017002767A1 (es) | Nuevas proteínas específicas para cd137. | |
| PE20191033A1 (es) | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) | |
| MX385926B (es) | Proteínas de fusión de citoquinas. | |
| MX2022013945A (es) | Nuevas proteinas de union a repeticiones de anquirina y sus usos. | |
| BR112014032316A2 (pt) | proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta | |
| BR112017028205A2 (pt) | molécula de rna, vetor, célula hospedeira, composição farmacêutica, kit, e, uso de uma ou mais utrs. | |
| CO2018005915A2 (es) | Aglutinantes de tnf mejorados | |
| HRP20220531T1 (hr) | Varijabilni fragmenti antitijela koji se umeću i modificirane a1-a2 domene nkg2d liganda | |
| BR112015004696A2 (pt) | polipeptídeos quiméricos tendo especificidade de ligação alvejada | |
| MX2021000401A (es) | Nuevas proteinas de fusion especificas para cd137 y pd-l1. | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| EA201590611A1 (ru) | Новые молекулы, связывающие il-17a, и их медицинское применение | |
| BR112014020164A2 (pt) | proteínas pesticidas manipuladas | |
| EA201491643A1 (ru) | Идентификация мутаций канал-опсина-2 (chop2) и способы применения | |
| MX2018006559A (es) | Nuevos polipeptidos de fusion anti-angiogenicos. | |
| BR112014028130A2 (pt) | Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos | |
| DOP2018000001A (es) | Moléculas de fusión | |
| ES2526109R2 (es) | Péptido y composición farmacéutica para el tratamiento del cáncer | |
| EA201992587A1 (ru) | Пептиды и их применение в качестве противовирусных агентов | |
| EA202092327A1 (ru) | Варианты lfa3 и их композиции и применение | |
| MX2020009877A (es) | Péptidos neutralizantes de miotoxina. | |
| CY1113614T1 (el) | H5 πρωτεϊνες, μορια νουκλεϊνικου οξεος και φορεις που κωδικοποιουν αυτες και ιατρικη χρηση αυτων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |